Tabula Rasa HealthCare Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Tabula Rasa HealthCare wird ein Gewinn- und Umsatzwachstum von 77.5% bzw. 13.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 78.7% pro Jahr wachsen soll.

Wichtige Informationen

77.5%

Wachstumsrate der Gewinne

78.7%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	26.9%
Wachstumsrate der Einnahmen	13.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Jul 26

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Jun 28

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Jun 05

Tabula Rasa HealthCare, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 60% Above Its Share Price

Apr 02

Tabula Rasa HealthCare (NASDAQ:TRHC) Is Carrying A Fair Bit Of Debt

Mar 12

Update: Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Gained 51% In The Last Three Years

Feb 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:TRHC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	469	-8	N/A	N/A	1
12/31/2024	416	-15	N/A	N/A	4
12/31/2023	362	-31	N/A	N/A	4
6/30/2023	338	-61	-24	-5	N/A
3/31/2023	321	-64	-9	14	N/A
12/31/2022	300	-77	-21	7	N/A
9/30/2022	286	-72	-14	22	N/A
6/30/2022	277	-58	-15	23	N/A
3/31/2022	268	-59	-34	4	N/A
12/31/2021	260	-52	-20	15	N/A
9/30/2021	268	-70	-27	2	N/A
6/30/2021	271	-80	-24	2	N/A
3/31/2021	283	-80	-22	2	N/A
12/31/2020	221	-57	-17	5	N/A
9/30/2020	293	-57	-16	6	N/A
6/30/2020	297	-44	-10	13	N/A
3/31/2020	297	-36	-4	20	N/A
12/31/2019	285	-32	-29	-6	N/A
9/30/2019	269	-36	-20	0	N/A
6/30/2019	249	-18	-20	-4	N/A
3/31/2019	221	-40	-23	-11	N/A
12/31/2018	204	-47	5	16	N/A
9/30/2018	190	-26	7	16	N/A
6/30/2018	169	-30	7	15	N/A
3/31/2018	149	-3	9	17	N/A
12/31/2017	133	13	12	18	N/A
9/30/2017	117	-3	10	16	N/A
6/30/2017	109	-8	1	7	N/A
3/31/2017	102	-7	N/A	4	N/A
12/31/2016	95	-3	N/A	7	N/A
9/30/2016	87	4	N/A	3	N/A
6/30/2016	80	-11	N/A	9	N/A
3/31/2016	75	-12	N/A	7	N/A
12/31/2015	70	-13	N/A	3	N/A
9/30/2015	64	-20	N/A	3	N/A
6/30/2015	59	-6	N/A	3	N/A
3/31/2015	53	-5	N/A	3	N/A
12/31/2014	48	-5	N/A	1	N/A
12/31/2013	25	-9	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TRHC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TRHC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TRHC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TRHCDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: TRHCDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TRHC in 3 Jahren voraussichtlich hoch sein wird

Tabula Rasa HealthCare Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

Price target increased by 11% to US$7.30

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO, President & Director exercised options and sold US$117k worth of stock

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$7.30

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Price target decreased to US$5.92

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Consensus forecasts updated

Price target increased to US$6.42

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Price target increased to US$6.75

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

Price target decreased to US$5.71

Price target decreased to US$6.33

Continuing To Avoid Tabula Rasa HealthCare Inc.

Consensus revenue estimates fall by 25%

Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$9.92

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought US$58k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 22% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Calculating The Fair Value Of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Co-President recently sold US$95k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Why Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Could Be Worth Watching

Insufficient new directors

Co-Founder recently sold US$2.9m worth of stock

Third quarter 2021 earnings released: US$0.73 loss per share (vs US$0.99 loss in 3Q 2020)

Price target decreased to US$46.71

Is Tabula Rasa HealthCare (NASDAQ:TRHC) A Risky Investment?

Tabula Rasa and Hesperos Receive $1.9 Million National Institutes of Health Award for Research Focused on Preventable Drug-Induced Alzheimer's Disease

Chief Operating Officer recently sold US$90k worth of stock

Second quarter 2021 earnings released: US$0.91 loss per share (vs US$0.66 loss in 2Q 2020)

Tabula Rasa Healthcare, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2021 and Year Ending December 31, 2021

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?